Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Novo Nordisk (whose injectable weight-loss medication Wegovy is shown here) and rival Eli Lilly are both developing a new generation of obesity drugs. Eli Lilly and Novo Nordisk - the dominant players ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

A treatment for alopecia areata could move forward despite a setback in a midstage clinical trial.

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push a new generation of obesity treatments while making sweeping changes to ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

This is the third of four planned U.S. manufacturing sites the pharmaceutical giant has unveiled this year, set to bring 450 ...